Sakar Healthcare Limited (NSE: SAKAR) is a Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹2,140 Cr, it ranks #1,207 by market cap among the 6,137 Indian listed companies on FinBizNet, and #20 of 63 in Pharmaceuticals. At ₹889.80 (as of 25 Oct 2026), the share price is 27.6% below its 52-week high of ₹1,229.85 and 153.1% above its 52-week low of ₹351.50. The share price is up 152.1% over one year and up 10.9% over three months.
| Current Price | ₹889.80 |
|---|---|
| Market Cap | ₹2,140 Cr |
| NSE Symbol | SAKAR |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 67.5 |
| Return on Equity | 9.99% |
| Return on Assets | 6.51% |
| 52-Week Range | ₹351.50 – ₹1,229.85 |
| 1-Year Price Change | +152.1% |
| 3-Month Price Change | +10.9% |
| Beta (1Y) | -0.22 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.sakarhealthcare.com |
| Revenue | ₹87 Cr |
|---|---|
| Net Profit | ₹11 Cr |
| Net Margin | 12.9% |
| EPS (Basic) | ₹5.08 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-inflammatory, antiemetic, anticonvulsant, antipsychotic, antidepressant, and anti-cancer. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
1. Manufacturing of Pharmaceutical Products-This segment manufactures and sells pharmaceutical products in various forms, such as liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectables in ampoules and vials, and lyophilized injections.
1. Manufacturing of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Sakar Healthcare Limited | ₹2,140 Cr | 67.5 | 9.99% | ₹87 Cr | +152.1% |
Listed by market capitalisation. Ratios are shown for context only.
Sakar Healthcare Limited is trading at ₹889.80, with a market capitalisation of ₹2,140 Cr.
Sakar Healthcare Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sakar Healthcare Limited has a P/E of 67.5 and a return on equity of 9.99%.
Sakar Healthcare Limited is listed on the NSE under the symbol SAKAR.
Sakar Healthcare Limited's share price is up 152.1% over one year and up 10.9% over three months. Its 52-week range is ₹351.50 to ₹1,229.85.
In Q2 FY27, Sakar Healthcare Limited reported revenue of ₹87 Cr and net profit of ₹11 Cr, with basic EPS of ₹5.08 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.